Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GENPAD genotype-guided antithrombotic treatment in peripheral arterial disease
NL-OMON50838Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of clopidogrel, rivaroxaban and aspirin in arteriosclerosis obliterans and lower extremity arterial disease (LEAD) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Primary composite arterial thrombotic outcome at 24 months. Started Mar 2021; status: recruiting.
02
Drugs
clopidogrelrivaroxabanaspirin
03
Conditions
arteriosclerosis obliteranslower extremity arterial disease (LEAD)
Beyond the preview
Go deeper on NL-OMON50838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50838.